

Department of Chemistry



# Enantioselective analysis of chiral pharmacologically active compounds in urban water


***Barbara Kasprzyk-Hordern***

University of Bath, Department of Chemistry, Faculty of Science, Bath, BA2 7AY, UK

## AIMS

- ❖ To introduce the phenomenon of chirality
- ❖ To present methodological advances in the analysis of chiral drugs at enantiomeric level in environmental matrices
- ❖ To discuss results of enantiomeric profiling of chiral drugs in environmental matrices

## Phenomenon of chirality



## PRINCIPLES OF CHIRALITY

**Enantiomers of the same chiral molecule have similar physico-chemical properties but may differ in their biological properties**

### **Enantiomers of chiral drugs reveal different potency:**

- *S*(+)-enantiomers of AMPH-derived drugs have much higher stimulant activity than *R*(-)-enantiomers
- *S*(+)-MDMA is more amphetamine-like stimulant and *R*(-)-MDMA is more hallucinogenic
- *S*-ibuprofen is 100x more potent than *R*-ibuprofen
- *S*(-)-enantiomers of beta-blockers reveal much higher potency in humans
- Cardiovascular effects of verapamil are mediated by *S*(-)-enantiomer

### **Chiral drugs have stereoselective disposition in the body:**

- *S*(+)-enantiomers of amphetamine-derived drugs metabolise faster in human than *R*(-)-enantiomers

## ENVIRONMENTAL LIFE-CYCLE OF PACs








- ❖ The enantiomeric composition of a chiral molecule can change throughout its environmental life-cycle
- ❖ The very same chiral molecule might have different activity/toxicity at different stages of its environmental life cycle, which will depend on its origin and exposure to environmental factors


- ❖ **NSAIDs, analgesics and anaesthetics**
- ❖ **CNS drugs:** antipsychotic drugs, antidepressants, sedative/hypnotics, CNS stimulants and drugs used for ADHD, drugs used in neurological disorders
- ❖ **Cardiovascular drugs:** lipid regulating drugs, beta-adrenoceptor blocking drugs, antihypertensives, anticoagulants, calcium channel blockers, anti-arrhythmic drugs
- ❖ **Respiratory drugs:** bronchodilators, antihistamines, decongestants
- ❖ **Gastro-intestinal drugs:** proton pump inhibitors, H<sub>2</sub>-receptor antagonists
- ❖ **Antimicrobials**
- ❖ **Antineoplastics**
- ❖ **Illicit drugs**

## STUDIED CHIRAL DRUGS


### Amphetamines




### Antidepressants




### Beta-blockers




....AND MANY MORE....



**RP (C18)-UPLC-QqQ**




**RP-chiral (CBH) LC-QqQ**



**Ephedrine/  
Pseudoephedrine**

1R,2S(-)-Ephedrine and 1S,2S(+)-pseudoephedrine loads in sewage (sum of loads from 7 WWTPs)





## ANALYSIS OF CHIRAL DRUGS IN LIQUID MATRICES


### SPE (HLB, 60mg)

Condition: 4mL MeOH, 4mL H<sub>2</sub>O; Sample load: 100mL wastewater; 500mL river water; Elution: 4mL MeOH; Evaporation and reconstitution to 0.5mL with mobile phase

### UPLC


#### Column 1: CBH

(100x2.1mm;  
5µm);  
90% H<sub>2</sub>O, 10%  
IPA, 1mM  
NH<sub>4</sub>OAc;  
25°C, 0.075  
mL/min; isocratic



#### Column 2: Chirobiotic V

(250x2.1mm;  
5µm);  
100% MeOH,  
4mM NH<sub>4</sub>OAc,  
0.005% HCOOH;  
25°C, 0.1 mL/min;  
isocratic



### Mass Spectrometry







#### MS1:

(ESI+) **QqQ** (Waters TQD)

#### MS2:

(ESI+) **QTOF** (microTOFQ, Bruker)

Validation			
Parameters:	UPLC (CBH)-QqQ	UPLC (CBH)-QTOF	UPLC (Chirobiotic V-QTOF)
Accuracy	<20%	<20%	<20%
Precision	<10%	<10%	<10%
MQLs (wastewater)	1.2-5.8 ng/L (INFL)	-	1.3-86 ng/L (EFFL)
MQLs (river)	0.2-1.2 ng/L	9.1-51.7 ng/L	0.3-39 ng/L
Linearity range	0.05-500 µg/L	0.5-500 µg/L	0.25-100 µg/L 5-500 µg/L




## LC-MS/MS chromatograms of chiral drugs in wastewater influent


### Column:

CBH (100x2.1mm; 5 $\mu$ m);  
90% H<sub>2</sub>O, 10% IPA, 1mM  
NH<sub>4</sub>OAc;  
25°C, 0.075 mL/min; isocratic

### MS:

TQD





**LC-MS/MS chromatograms of chiral drugs in river water spiked with chiral drugs and extracted by SPE (concentration, 100 ng/L)**

**Column:**

CBH (100x2.1mm; 5µm);  
90% H<sub>2</sub>O, 10% IPA, 1mM NH<sub>4</sub>OAc;  
25°C, 0.075 mL/min; isocratic

**MS:**

QTOF



## LC-MS/MS chromatograms of chiral drugs in river water spiked with chiral drugs and extracted by SPE (concentration, 100 ng/L)

### Column:

Chirobiotic V (100 x 2.1mm; 5µm);  
100% MeOH, 4mM NH<sub>4</sub>OAc; 0.005%FA  
25°C, 0.1 mL/min; isocratic



### MS:

QTOF

## ENANTIOMERIC PROFILING OF CHIRAL DRUGS IN ENVIRONMENTAL MATRICES AND ITS APPLICATIONS:

- ❖ Wastewater treatment – enantiomeric profiling via targeted analysis with chiral-UPLC-TQD
- ❖ Environmental monitoring – enantiomeric profiling via targeted analysis with chiral-UPLC-TQD
- ❖ Mechanisms of degradation of chiral drugs in microcosm experiments – screening of unknowns with chiral UPLC-QTOF
- ❖ Enantiomeric profiling in human epidemiology









# Drugs of abuse in a river catchment



- |                |                      |                   |
|----------------|----------------------|-------------------|
| ■ Ephedrine    | ■ Sildenafil         | ■ Norketamine     |
| ■ Ketamine     | ■ Venlafaxine        | ■ Norfluoxetine   |
| ■ Fluoxetine   | ■ Nortriptyline      | ■ Amitriptyline   |
| ■ Dosulepin    | ■ Oxazepam           | ■ Nordiazepam     |
| ■ Diazepam     | ■ Temazepam          | ■ Nortramadol     |
| ■ Tramadol     | ■ Norpropoxyphene    | ■ EMDP            |
| ■ EDDP         | ■ Methadone          | ■ Dihydrocodeine  |
| ■ Morphine     | ■ Oxycodone          | ■ Norcodeine      |
| ■ Codeine      | ■ 6-acetylmorphine   | ■ Continine       |
| ■ Nicotine     | ■ MDA                | ■ Caffeine        |
| ■ MDMA         | ■ Methamphetamine    | ■ TFMPP           |
| ■ BZP          | ■ Norbenzoylecgonine | ■ Amphetamine     |
| ■ Cocaethylene |                      | ■ Benzoylecgonine |
| ■ Cocaine      |                      |                   |


\*Results for 64 drugs of abuse, 12 month monitoring programme

# Drugs of abuse in WWTPs




\*Results for 64 drugs of abuse, 12 month monitoring programme








# ENANTIOSELECTIVE FATE OF ATENOLOL





$$EF = \frac{R(+)-\text{ATENOLOL}}{R(+)-\text{ATENOLOL} + S(-)-\text{ATENOLOL}}$$






# ENANTIOSELECTIVE FATE OF MDMA



$$EF = \frac{R(-)\text{-MDMA}}{R(-)\text{-MDMA} + S(+)\text{-MDMA}}$$




# Stereoselective biodegradation of AMP in river microcosms


$$EF = \frac{S(+)\text{AMPH}}{R(-)\text{AMPH} + S(+)\text{AMPH}}$$

$$EF = \frac{S(+)\text{METH}}{R(-)\text{METH} + S(+)\text{METH}}$$

- DAR- Dark Abiotic Reactor
- DBR- Dark Biotic Reactor
- LAR- Light Abiotic Reactor
- LBR- Light Biotic Reactor



# HUMAN EPIDEMIOLOGY using wastewater profiling



## SEWAGE EPIDEMIOLOGY

● CONCEPTUALLY SIMPLE ● METHODOLOGICALLY SOPHISTICATED

## SEWPROF ITN

*A new paradigm in drug use and human health risk assessment: Sewage profiling at the community level*

HOME CONTACT EVENTS JOB OPPORTUNITIES NEWS PEOPLE 0 POSTS 0 COMMENTS

UNCATEGORIZED ADMIN

### Home

SEWPROF is a research project funded by the [European Commission, Marie Curie Actions, Seventh Framework Programme, Initial Training Network](#).

SEWPROF aims to develop inter-disciplinary and cross-sectoral research capability for the next generation of scientists working in the newly-emerging field of sewage epidemiology. It will provide an integrated approach towards public health monitoring at a community level based on innovative sewage epidemiology techniques. The approach will deliver real-time profiling of community-wide health and lifestyle through the analysis of human biomarkers in sewage using a wide-range of methods including hyphenated mass spectrometry techniques, bioanalytical techniques and real-time sensing. The innovative research strategy of obtaining epidemiological information from sewage has been pioneered by members of the SEWPROF team, and, although still in its infancy, is currently used to determine illicit drug use trends at community level via the analysis of urinary biomarkers in sewage. SEWPROF aims to advance knowledge of the epidemiology of (illicit) drug use and to bridge gaps in the available expertise with the ultimate goal of applying this cutting edge interdisciplinary approach within epidemiological studies of societal health. This conceptually simple but methodologically sophisticated epidemiological approach could become an early warning system for outbreaks of disease and a unique tool for the identification of hot-spots for pandemics.



### News

[Testing the waters: first international multidisciplinary conference on detecting illicit drugs in wastewater](#)

[SEWPROF website up and running!](#)

SEWPROF Initial Training Network is funded by the Marie Curie Actions of the European Union Seventh Framework Programme.



GO TO: [www.sewprof-itn.eu](http://www.sewprof-itn.eu)

# Daily consumption

$$mg\ day^{-1}\ 1000\ people^{-1} \frac{\left(\frac{100}{Excretion}\right)\left(\frac{MW_{Par}}{MW_{DTR}}\right)}{\frac{Population}{1000}} - OS$$

Compound	WWTP Influent	
	DTR	Daily usage (mg day <sup>-1</sup> 1000 people <sup>-1</sup> )
Cocaine	Benzoyllecgonine	250
Amphetamine	Amphetamine	286
Methamphetamine	Methamphet.	1
MDMA	MDMA	73
Oxycodone	Oxycodone	54 (NHS)   50
Dihydrocodeine	Dihydrocodeine	225 (NHS)   213
Methadone	Methadone	97
Amitriptyline	Nortriptyline	419 (NHS)   588
Fluoxetine	Fluoxetine	266 (NHS)   260
	Norfluoxetine	308

*Load* - amount of DTR arriving at the WWTP (g day<sup>-1</sup>);  
*Excretion* - the percentage excretion of the DTR after relevant forms of administration;  
*MW<sub>Par</sub>* - the molecular weight of the parent compound and *MW<sub>DTR</sub>* - the molecular weight of the DTR.  
*OS* - the amount of DTR that is present in wastewater due to other sources other than the parent compound, if applicable (mg day<sup>-1</sup> 1000 people<sup>-1</sup>).

## SEWAGE EPIDEMIOLOGY – IMPORTANCE OF ENANTIOMERIC PROFILING:



- ❖ Distinction between legal and illicit use of drugs
- ❖ Verification of the method of synthesis of illicit drugs
- ❖ Identification of whether drug residue results from consumption of illicit drug or metabolism of other (illicit) drug
- ❖ Verification of potency of abused drugs

## MDMA AND MDA


- ❖ No medical use
- ❖ Produced as racemate
- ❖ Metabolism favours *S*(+)-enantiomer
- ❖ Preferential metabolism of *S*(+)-MDMA leads to enrichment of MDMA with *R*(-)-enantiomer and formation of *S*(+)-MDA (twice as much *S*(+)-MDA is excreted in urine as compared to *R*(-)-MDA)





# MDMA in 7 WWTPs in England




$$EF = \frac{R(-)MDMA}{R(-)MDMA + S(+ )MDMA}$$



## MDA in 7 WWTPs in England



$$EF = \frac{R(-)MDA}{R(-)MDA + S(+ )MDA}$$



## Conclusions


Enantiomeric profiling of chiral drugs in environmental matrices:

- ❖ Provides invaluable information about environmental fate and toxicity of chiral drugs
- ❖ Should be incorporated into environmental risk assessment of chiral drugs
- ❖ Provides yet another dimension to sewage epidemiology as it helps with:
  - Distinction between legal and illicit use of drugs
  - Verification of the method of synthesis of illicit drugs
  - Identification of whether drug residue results from consumption of illicit drug or metabolism of other (illicit) drug
  - Verification of potency of abused drugs

# Acknowledgments



Main contributors:



Dr David Baker




Dr John Bagnall

**THANK YOU TO ENVIRONMENTAL CHEMISTRY GROUP AT BATH!**



## Funding received from:

- ❖ UK Natural Environment Research Council (Project No. NE/I000534/1)
- ❖ UK Engineering and Physical Sciences Research Council (Project No. EP/I038608/1 and EP/J501402/1)
- ❖ EU, FP7, Marie Curie Actions (Project No. 317205)



Supported by:

